A comparison of vaccine technologies to be presented at the asm microbe conference

Advanced subunit vaccine technology, including suvax™ and marvax™, to be discussed alongside mrna and viral vectored vaccine approaches princeton, n.j., june 14, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that professor axel lehrer, university of hawaiʽi at mĀnoa (uhm), will be presenting key data from the company's thermostable vaccine technology platform developed in collaboration with uhm, including results from the filovirus vaccine candidates for both sudan ebolavirus (suvax™) and marburg marburgvirus (marvax™).
SNGX Ratings Summary
SNGX Quant Ranking